Prices delayed by at least 15 minutes | Print
Novo-Nordisk A/S (NVO)
ADRThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Address
Novo Allé
Bagsværd
DNK
2880
Telephone
+45 30759085
Forecast key dates
Name | Key Date |
---|---|
Novo Nordisk A/S Annual General Meeting for 2025 | 2025-03-21T14:00:00 |
Novo Nordisk A/S Fourth Quarter Earnings Results for 2024 | 2025-01-31T00:00:00 |
Novo Nordisk A/S Fourth Quarter Earnings Conference Call for 2024 | 2025-01-31T00:00:00 |
Novo Nordisk A/S Annual Report for 2024 | 2025-01-31T00:00:00 |
Novo Nordisk A/S Third Quarter Earnings Result for 2024 | 2024-11-06T00:00:00 |
Novo Nordisk A/S Third Quarter Earnings Conference Call for 2024 | 2024-11-06T00:00:00 |
Novo Nordisk A/S Second Quarter Earnings Result for 2024 | 2024-08-07T00:00:00 |
Novo Nordisk A/S Second Quarter Earnings Conference Call for 2024 | 2024-08-07T00:00:00 |
Novo Nordisk A/S First Quarter Earnings Results for 2024 | 2024-05-02T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
Novo Nordisk A/S Annual General Meeting for 2024 | 2024-03-21T14:00:00 |
Novo Nordisk A/S Annual Report for 2023 | 2024-01-31T00:00:00 |
Novo Nordisk A/S Third Quarter Earnings Conference Call for 2023 | 2023-11-02T13:00:00 |
Novo Nordisk A/S Third Quarter Earnings Result for 2023 | 2023-11-02T00:00:00 |
Novo Nordisk A/S Second Quarter Earnings Result for 2023 | 2023-08-10T00:00:00 |
Novo Nordisk A/S First Quarter Earnings Results for 2023 | 2023-05-04T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.